IL-16 anti-HIV-1 therapy [3]

Nature Medicine

Volumn 3, Issue 9, 1997, Pages 938-

  Viglianti, G A ^a   Parada, N A ^a   Maciaszek, J W ^a   Kornfeld, H ^a   Center, D M ^a   Cruikshank, W W ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CYTOKINE; INTERLEUKIN 16; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; MESSENGER RNA; RECOMBINANT INTERLEUKIN 16; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENTIATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; MONONUCLEAR CELL; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TRANSCRIPTION REGULATION; VIRUS INFECTION; VIRUS INHIBITION; VIRUS REPLICATION;

ANTI-HIV AGENTS; CD4-POSITIVE T-LYMPHOCYTES; GENES, VIRAL; GENETIC ENGINEERING; HIV INFECTIONS; HIV-1; HUMANS; INTERLEUKIN-16; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0030756575     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm0997-938     Document Type: Letter

References (3)